HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Extends Afrin Line With First OTC Oxymetazoline Spray In US For Children Under 6

Executive Summary

Children’s Afrin regular and no-drip formulations reach US stores with consumers having choices between dozens of oxymetazoline nasal sprays available under an FDA OTC monograph. But products indicated for children was limited to one, Mucinex Childrens Stuffy Nose, and it’s for children 6 and up.

You may also be interested in...



India Proposes OTC List In Draft Rule Lacking Clarity On Pricing, Switching Pathway

India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?

No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul

Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.  

US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language

AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS153136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel